University of Colorado School of Medicine

Endocrine Cancer Expert Named Associate Chief of Surgery at NYU Langone Hospital--Brooklyn

Retrieved on: 
Thursday, August 12, 2021
Yale New Haven Hospital, Thyroid cancer, NYU Langone Health, Johns Hopkins Hospital, Thyroid disease, Air pollution, Doctor of Philosophy, Science, University, Parathyroidectomy, Program, Department, Research, General surgery, University of Colorado School of Medicine, Exocrine gland, Patient, Particulates, Johns Hopkins School of Medicine, NYU, Incidence, Endocrine disease, Education, Johns Hopkins, Therapy, Pharmaceutical industry, Dentistry, Medicine

NEW YORK, Aug. 12, 2021 /PRNewswire/ --Nationally renowned endocrine cancer expert Jason D. Prescott, MD, PhD , has been named associate chief of surgery for research and academic affairs at NYU Langone HospitalBrooklyn.

Key Points: 
  • NEW YORK, Aug. 12, 2021 /PRNewswire/ --Nationally renowned endocrine cancer expert Jason D. Prescott, MD, PhD , has been named associate chief of surgery for research and academic affairs at NYU Langone HospitalBrooklyn.
  • In addition to his clinical work, Dr. Prescott will oversee and expand clinical research projects that will elevate NYU Langone HospitalBrooklyn in areas of therapeutics, academics, and teaching.
  • He also will establish new patient clinics at NYU Langone HospitalBrooklyn and will have surgical privileges in Brooklyn and at NYU Langone's Tisch Hospital and Kimmel Pavilion.
  • While at Johns Hopkins Medical Center, Dr. Prescott served as chief of endocrine surgery,performing between 350 and 400 surgeries annually.

Ancilia Biosciences Awarded NSF Grant to Advance Platform Designed to Address Overlooked Obstacle to Success for Microbiome Therapeutics

Retrieved on: 
Tuesday, August 3, 2021
Microbiomes, Bacteriology, Environmental microbiology, Branches of biology, Bacteriophage, Biology, Gut microbiota, Organisms, Articles, Microbiome

We founded Ancilia to overcome what our researchers believe is a significant obstacle to this successthe failure to address the presence of phages that infect commensal microbiome bacteria.

Key Points: 
  • We founded Ancilia to overcome what our researchers believe is a significant obstacle to this successthe failure to address the presence of phages that infect commensal microbiome bacteria.
  • There is evidence that phages are associated with disease and that they may also compromise the efficacy of LBPs.
  • We are delighted that the NSF sees potential in our technology and is supporting further development of our platform."
  • Ancilia Biosciences ( www.anciliabio.com) is developing virus-resistant live bacterial biotherapeutics (LBPs) to alter the gut microbiome and treat disease.

University of Colorado School of Medicine and AristaMD Partner to Expand eConsults to Community Providers

Retrieved on: 
Tuesday, September 22, 2020
Technology, Hospitals, Other Technology, Telecommunications, Software, Practice Management, Other Health, Internet, General Health, Health, Articles, University of Colorado Denver, Anschutz Medical Campus, Technology, Telehealth, Science and technology, University of Colorado, CU, Telemedicine, AristaMD, University of Colorado School of Medicine

AristaMD , an innovative telehealth platform that delivers primary care providers (PCPs) timely and documented specialist insight through eConsults , has partnered with the University of Colorado School of Medicine (CU) to expand eConsults to a network of community providers.

Key Points: 
  • AristaMD , an innovative telehealth platform that delivers primary care providers (PCPs) timely and documented specialist insight through eConsults , has partnered with the University of Colorado School of Medicine (CU) to expand eConsults to a network of community providers.
  • The AristaMD platform works with all EHRs, seamlessly integrates into physician workflows, and will allow us to scale to community providers throughout the state of Colorado as the partnership grows.
  • AristaMD will empower primary care providers with the ability to conduct eConsults with specialists from the University of Colorado School of Medicine, who will provide recommended treatment pathways for specific patient cases.
  • The school is located on the Anschutz Medical Campus , one of four campuses in the University of Colorado system.

$120 Million Gift from Phil Anschutz and The Anschutz Foundation Accelerates Shared Vision of Establishing the University of Colorado Anschutz Medical Campus as Medical Destination

Retrieved on: 
Tuesday, August 21, 2018
Colorado, University of Colorado Denver, Anschutz Medical Campus, University of Colorado Hospital, University of Colorado, Children's Hospital Colorado, Philip Anschutz, University of Colorado School of Medicine

This gift brings The Anschutz Foundation's total investment in the University of Colorado Anschutz Medical Campus to nearly $300 million since 2000.

Key Points: 
  • This gift brings The Anschutz Foundation's total investment in the University of Colorado Anschutz Medical Campus to nearly $300 million since 2000.
  • "We are proud partners in the development of the University of Colorado Anschutz Medical Campus and share an ambitious vision for further elevating it among the country's top medical destinations," said Mr. Anschutz.
  • "UCHealth and University of Colorado Hospital partner with the University of Colorado Anschutz Medical Campus to leverage research and innovative treatments like immunotherapy to transform the future of health care.
  • Scheduled to open in Spring 2019, the new Children's Hospital Colorado, Colorado Springs will be the first pediatric-only hospital in southern Colorado.